Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FBIOP | US
-0.11
-0.79%
Healthcare
Biotechnology
30/06/2024
09/04/2026
13.78
13.77
13.96
13.60
Fortress Biotech Inc. a biopharmaceutical company develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101 an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302 an anti-GITR; CK-303 an anti-CAIX; and ONCOlogues and oligonucleotide platform. It has collaboration arrangements with universities research institutes and pharmaceutical companies. The company was formerly known as Coronado Biosciences Inc. and changed its name to Fortress Biotech Inc. in April 2015. Fortress Biotech Inc. was incorporated in 2006 and is based in Bay Harbor Islands Florida.
View LessPositive Momentum
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Risky Dividend Yield (> 12%). Dividend cuts imminent.
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
31.1%1 month
36.6%3 months
72.7%6 months
67.2%-
-
-
4.95
0.61
-
-
-
-90.31M
73.97M
73.97M
40.69
-168.76
-
-14.30
-1.74K
0.04
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.55
Range1M
1.80
Range3M
4.99
Rel. volume
0.20
Price X volume
40.47K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.04 | 79.93M | 14.80% | n/a | 0.00% |
| iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 5.75 | 78.16M | -4.64% | n/a | -2140.66% |
| CRDF | CRDF | Biotechnology | 1.67 | 77.74M | 7.05% | n/a | 3.52% |
| Humacyte Inc | HUMA | Biotechnology | 0.607 | 76.07M | -6.83% | n/a | -63.37% |
| Tenaya Therapeutics Inc. Common Stock | TNYA | Biotechnology | 0.74 | 75.59M | 2.04% | n/a | 11.62% |
| BeyondSpring Inc | BYSI | Biotechnology | 1.77 | 71.33M | 0.57% | n/a | -14.90% |
| XBiotech Inc | XBIT | Biotechnology | 2.33 | 70.98M | -0.43% | n/a | 5.08% |
| MediciNova Inc | MNOV | Biotechnology | 1.42 | 69.65M | -1.39% | n/a | 0.86% |
| Coya Therapeutics Inc. Common Stock | COYA | Biotechnology | 4.53 | 68.95M | 10.22% | n/a | 0.00% |
| PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.33 | 68.52M | 6.40% | n/a | 6.06% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.62 | 72.76M | -1.53% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.55 | 64.11M | 4.41% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.16 | 16.95M | -4.13% | 0.03 | 16.03% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 11.02 | 16.78M | 94.36% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.651 | 12.58M | -0.82% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3 | 3.32M | 2.85% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2987 | 2.84M | 10.96% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.95 | 1.07M | -3.47% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | - | - |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | - | 15.55 | - |
| Dividend Yield | 40.69 | - | Leader |
| Std. Deviation (3M) | 72.71 | - | Par |
| Debt to Equity | 4.95 | -1.23 | Expensive |
| Debt to Assets | 0.61 | 0.25 | Expensive |
| Market Cap | 73.97M | - | Emerging |